➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim

Last Updated: January 15, 2021

DrugPatentWatch Database Preview

CAFCIT Drug Profile

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

When do Cafcit patents expire, and what generic alternatives are available?

Cafcit is a drug marketed by Hikma and is included in one NDA.

The generic ingredient in CAFCIT is caffeine citrate. There are eleven drug master file entries for this compound. Eight suppliers are listed for this compound. Additional details are available on the caffeine citrate profile page.

US ANDA Litigation and Generic Entry Outlook for Cafcit

A generic version of CAFCIT was approved as caffeine citrate by EXELA PHARMA SCIENCE on September 21st, 2006.

  Start Trial

Drug patent expirations by year for CAFCIT
Drug Prices for CAFCIT

See drug prices for CAFCIT

Recent Clinical Trials for CAFCIT

Identify potential brand extensions & 505(b)(2) entrants

University of North Carolina, Chapel HillPhase 1
Thrasher Research FundPhase 1
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)Phase 3

See all CAFCIT clinical trials

US Patents and Regulatory Information for CAFCIT

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Exclusivity Expiration
Hikma CAFCIT caffeine citrate SOLUTION;INTRAVENOUS 020793-001 Sep 21, 1999 AP RX Yes Yes   Start Trial   Start Trial   Start Trial
Hikma CAFCIT caffeine citrate SOLUTION;ORAL 020793-002 Apr 12, 2000 AA RX Yes Yes   Start Trial   Start Trial   Start Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Exclusivity Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.